CLDN6 and CLDN9 dual targeting antibody drug conjugates for the treatment of ovarian and endometrial cancers.

被引：0
|
作者：
Du, Liang [1 ]
Zhang, Hongyan [1 ]
Jin, Lina [1 ]
Chen, Yali [1 ]
Wan, Tingting [1 ]
Xu, Liuliu [1 ]
机构：
[1] Shanghai Genechem Co Ltd, Shanghai, Peoples R China
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
912
引用
收藏
页数：1
相关论文
共 26 条
  • [21] Targeting cadherin-6 (CDH6) with an antibody-drug conjugate for the treatment of ovarian and renal cancer
    Collins, Scott D.
    Saxena, Parmita
    Li, Xiao Y.
    Shim, Yeonju
    Ostrom, Lance
    Yoder, Nicholas C.
    Catcott, Kalli C.
    McShea, Molly A.
    Sun, Xiuxia
    Bilic, Sanela
    Tschantz, William R.
    Flaherty, Meghan
    Mansfield, Keith
    Hu, Tiancen
    Capka, Vladimir
    Kurz, Markus
    Rajlic, Ivana Liric
    London, Anne Serdakowski
    Duc Nguyen
    Mosher, Rebecca
    Meyer, Matthew J.
    Bourret, Aaron
    Saeh, Jamal
    Cameron, Scott
    Lees, Emma
    Bialucha, Carl U.
    CANCER RESEARCH, 2016, 76
  • [22] XMT-1660: A Phase 1b trial of a B7-H4 targeting antibody drug conjugate (ADC) in endometrial, ovarian, and breast cancers
    Hamilton, Erika
    Spira, Alexander
    Adams, Sylvia
    Abuhadra, Nour
    Giordano, Antonio
    Parajuli, Ritesh
    Han, Hyo
    Weise, Amy
    Marchesani, Aubri
    Josephs, Kate
    Chaudhry, Arvind
    Kalinsky, Kevin
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S158 - S158
  • [23] XMT-1660: A PHASE 1B TRIAL OF A B7-H4 TARGETING ANTIBODY DRUG CONJUGATE (ADC) IN ENDOMETRIAL, OVARIAN, AND BREAST CANCERS
    Hamilton, Erika
    Chaudhry, Arvind
    Spira, Alex
    Adams, Sylvia
    Abuhadra, Nour
    Giordano, Antonio
    Parajuli, Ritesh
    Han, Hyo
    Weise, Amy
    Marchesani, Aubri
    Josephs, Kate
    Im, Ellie
    Shin, Chu Ri
    Kalinsky, Kevin
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A228 - A229
  • [24] Remarkable In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to the Tubulin-Disrupting Maytansinoid DM4, in Biologically Aggressive (Type II) Endometrial Cancers.
    Altwerger, Gary
    Bonazzoli, Elena
    Bellone, Stefania
    Egawa-Takata, Tomomi
    Menderes, Gulden
    Pettinella, Francesca
    Riccio, Francesco
    Feinberg, Jacqueline
    Zammataro, Luca
    Han, Chanhee
    Yadav, Ghanshyam
    Dugan, Katherine
    Morneault, Ashley
    Ponte, Jose F.
    Buza, Natalia
    Hui, Pei
    Wong, Serena
    Litkouhi, Babak
    Ratner, Elena
    Silasi, Dan-Arin
    Huang, Gloria S.
    Azodi, Masoud
    Schwartz, Peter E.
    Santin, Alessandro D.
    REPRODUCTIVE SCIENCES, 2018, 25 : 90A - 91A
  • [25] Stability and safety evaluation of STRO-002, a site-specific anti-folate receptor alpha antibody-drug conjugate for the potential treatment of ovarian and endometrial cancers
    Solis, Willy
    De Almeida, Venita
    Abrahams, Cristina
    Li, Xiaofan
    Heibeck, Tyler
    Bruhns, Maureen
    Galan, Adam
    Hoffman, Heidi
    Kiss, Robert
    Hallam, Trevor
    Lupher, Mark
    CANCER RESEARCH, 2019, 79 (13)
  • [26] Phase I study of the tissue factor-targeting antibody-drug conjugate XB002 among patients with advanced solid tumors (JEWEL-101): Design of expansion cohorts for endometrial, epithelial ovarian, and cervical cancers
    Syed, Mustafa
    Tolcher, Anthony
    Johnson, Melissa
    Weiss, Mia
    Vandross, Andrae
    Vidal-Cardenas, Sofia
    Ulahannan, Susanna
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S280 - S280
123